Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone

Journal of Biomaterials Applications
Saeed GhanbarzadehArash Khorrami

Abstract

pH-sensitive liposomes are designed to undergo acid-triggered destabilization. In the present study, we prepared polymer-modified, plasma stable, pH-sensitive fusogenic mitoxantrone liposomes to increase efficacy and selectivity on cancer cell lines. Conventional liposomes were prepared using cholesterol and dipalmitoyl-sn-glycero-3-phosphatidylethanolamine. Dioleoylphosphatidylethanolamine and a cholesteryl derivative, poly(monomethylitaconate)-co-poly(N,N-dimethylaminoethyl methacrylate) (PMMI-co-PDMAEMA), were used for the preparation of pH-sensitive fusogenic liposomes. Using polyethylene glycol (PEG)-poly(monomethylitaconate)-CholC6 (PEG-PMMI-CholC6) copolymers instead of cholesterol introduced pH-sensitive and plasma stability properties simultaneously in prepared liposomes. All formulations were prepared by thin film hydration method and subsequently, pH-sensitivity and stability in human serum were evaluated. The ability of pH-sensitive fusogenic liposomes to enhance the mitoxantrone cytotoxicity and selectivity in cancerous cell lines was assessed in vitro compared to normal cell line using human breast cancer cell line (MCF-7), human prostate cancer cell line (PC-3), and human umbilical vein endothelial cells line. Re...Continue Reading

References

Aug 1, 1990·Toxicology·S F Llesuy, S L Arnaiz
Apr 1, 1993·Leukemia Research·B Sundman-EngbergC Paul
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L BjermerR Henriksson
Nov 26, 1997·Biochimica Et Biophysica Acta·R CazzolaB Cestaro
Jun 6, 2000·Advanced Drug Delivery Reviews·M Willis, E Forssen
Oct 26, 2000·European Journal of Pharmacology·A ChugunT Akera
Nov 18, 2000·Progress in Lipid Research·D C DrummondJ Leroux
Apr 7, 2004·Advanced Drug Delivery Reviews·Sérgio SimõesMaria C Pedroso de Lima
Jul 21, 2004·Journal of the Neurological Sciences·Oliver NeuhausHans-Peter Hartung
Mar 31, 2005·Journal of Neuroradiology. Journal De Neuroradiologie·A TourbahO Lyon-Caen
Aug 13, 2005·Pharmacology & Therapeutics·Oliver NeuhausHans-Peter Hartung
Oct 20, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M NiangP Tomsík
Mar 27, 2007·Journal of Colloid and Interface Science·Eun Chul ChoIh-Seop Chang
May 29, 2007·Advanced Drug Delivery Reviews·Ho Lun WongXiao Yu Wu
Oct 12, 2007·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Denitsa MomekovaNikolay Lambov
May 20, 2008·International Journal of Pharmaceutics·Tamer ShehataToshikiro Kimura
Jun 25, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Chunlei LiYongli Wang
Jun 28, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·ChunLei LiYongLi Wang
Jul 5, 2008·International Journal of Pharmaceutics·ChunLei LiYongLi Wang
Jul 26, 2008·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Chun-Chao ChangYu-Chih Liang
Jun 30, 2009·Colloids and Surfaces. B, Biointerfaces·Toshinori ShimanouchiRyoichi Kuboi
Jul 15, 2009·Trends in Pharmacological Sciences·Ariel Fernández, Sean Sessel
Dec 29, 2009·Colloids and Surfaces. B, Biointerfaces·Suk Hyun JungByung Cheol Shin
Mar 9, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eiji YubaKenji Kono
Apr 27, 2010·Biochemical Pharmacology·Edna Cukierman, David R Khan
Jun 24, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Rae Sung ChangYu-Kyoung Oh
Aug 24, 2010·Clinical Neurology and Neurosurgery·Annette WundesRichard A Nash
Aug 31, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·S DadashzadehA M Vali
Apr 22, 2011·International Journal of Pharmaceutics·Yuta YoshizawaKazutaka Higaki
Oct 15, 2011·Advanced Drug Delivery Reviews·Arnaud E FelberJean-Christophe Leroux
Jun 6, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sangbin LeeYu-Kyoung Oh
Jun 20, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Silvia Muro
Jul 18, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Il Keun KwonKinam Park
Oct 6, 2012·Advanced Drug Delivery Reviews·Theresa M Allen, Pieter R Cullis

❮ Previous
Next ❯

Citations

Jan 3, 2015·Nanoscale·Alexander A YaroslavovFredric M Menger
Nov 12, 2020·Polymers·Paweł MisiakAgnieszka Z Wilczewska
Mar 6, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Guoxing XuJin Pei

❮ Previous
Next ❯

Datasets Mentioned

BETA
GMBH

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.